Drug Development Consulting Services
Biopharma sponsors face mounting pressure to hit IND, NDA, and BLA milestones faster, without sacrificing regulatory integrity. Syner-G BioPharma delivers integrated drug development consulting services that provide direct technical execution across CMC, regulatory, quality, and medical writing. Rather than narrow contract staffing, our unified partner approach minimizes compliance risk at every phase.
Since 2007, our team of approximately 500 full-time specialists has supported biopharma and biotech sponsors across U.S. and international programs.
Integrating CMC, Regulatory, Quality, and Medical Writing
Drug development execution often fails when CMC evidence, regulatory strategy, and quality systems are built in silos. When these functions do not communicate, sponsors face costly document rework, mismatched files, and preventable clearance delays.
Our integrated drug development consulting services connect these core disciplines throughout your development lifecycle:
Development and Scale-up: Aligning laboratory data with clinical goals via strategic CMC consulting to simplify your development workflow.
Submission Strategy: Designing global regulatory pathways and managing agency interactions through a targeted regulatory strategy.
Document Execution: Authoring clean CTD modules and briefing packages with professional medical writing support.
Risk Mitigation: Building inspection readiness and QMS frameworks through active quality and compliance oversight.
By combining these functions under a unified management model, we eliminate handoff errors between separate contractors. Explore our complete range of capabilities through our service catalog to see how we align with your current operational gaps.
Flexible Consulting Models
Biopharma sponsors face fixed timelines dictated by investor milestones and regulatory dates, yet maintaining specialized internal staff for these peaks is rarely practical. Syner-G resolves this gap with transparent drug development consulting services tailored to your resource needs.
Fixed-Scope Milestones
Complete delivery of specific packages, such as FDA briefing documents or Module 3 readiness.
Retainer Advisory Access
Ongoing, on-demand strategic guidance for internal decision-makers.
Embedded Technical Blocks
Fractional to near-FTE resources integrated for intensive submission pushes.
Cost Drivers in Biopharma Development
Market rates scale by project scope, from targeted regulatory assessments to full program management. Costs depend on modality complexity (such as biologics), alongside urgency, data readiness, and active workstreams. To optimize your budget, our model uses full-time employees rather than contractors, eliminating onboarding delays and costly rework. Scoping a program starts with your goals, timeline, and risk profile.
The highest-cost drug development delays typically occur at critical inflection points:
- Pre-IND feedback
- Late-stage CMC readiness
- CDMO tech transfer
- Pre-approval inspections
Sponsors often face preventable regulatory holds from specific technical gaps. These typically involve weak stability strategies, inadequate impurity or potency rationales, container-closure issues, or weak control strategies. Unresolved comparability gaps between toxicology and clinical-trial materials also frequently stall programs during scale-up.
Technical CDMO Oversight and Complex Modalities
Through our drug development consulting services, we mitigate these risks using a hands-on management model. We help define technical requirements, run structured scorecard evaluations, align quality expectations, and manage physical tech transfer handoffs. For advanced modalities like cell and gene therapies, we resolve potency assay strategy complexity and cross-functional alignment. Secure digital platforms ensure data governance and traceability throughout the process.
Frequently Asked Questions About Drug Development Consulting
What drug development consulting services do you provide?
Syner-G provides integrated support across CMC, regulatory strategy, medical writing, quality compliance, and technical operations, including active CDMO oversight. Our engagements are milestone-driven and can target a single key deliverable or cover end-to-end program management. We do not operate wet labs or function as a contract manufacturing facility. View our service catalog to see our complete range of capabilities.
How much do drug development consulting services cost?
Consulting fees vary depending on development phase, molecule complexity, and engagement scope. Typical pricing models include:
- Project-based milestones
- Retainer-based strategic advisory
- Fractional technical blocks
Primary cost drivers include project urgency, modality complexity, data readiness, and the maturity of existing documentation.
Request a custom, scoped estimate to align our team with your pipeline milestones.
Can you support IND-enabling CMC and Module 3 readiness?
Yes. Syner-G specializes in regulatory submissions with a focus on phase-appropriate CMC strategy and Module 3 readiness. This includes establishing a robust control strategy, designing compliant stability and potency plans, and ensuring your technical data aligns with the regulatory narrative. By matching your development scale to current FDA expectations, we protect your program from unnecessary delay.
Do you only advise, or can you execute submissions and writing?
Both. Our consultants provide high-level strategic advisory and complete technical execution. They author, edit, and quality-check key deliverables, including briefing packages, Common Technical Document components, and formal agency responses. Visit our medical writing section or find pathway design details on our regulatory strategy page for more information.
How do you work with our CDMO and manage tech transfer risk?
Syner-G acts as an expert technical extension of your team to oversee CDMO partnerships and reduce tech transfer risks. Our team defines technical requirements, manages documentation requests, aligns quality expectations, and establishes clear governance structures between sponsors and manufacturers. While the CDMO handles the manufacturing process, we ensure all regulatory and quality evidence is captured accurately to support future submissions.
Can you support inspection readiness and quality system remediation?
Yes. Syner-G assists sponsors with inspection preparation and quality system remediation. Our team conducts diagnostic gap assessments, builds prioritized remediation roadmaps, conducts mock inspections, and harmonizes quality management systems across multiple manufacturing sites. These proactive steps keep your organization fully compliant before regulatory investigators arrive. Visit our quality and compliance page for detailed support options.
Partner With Syner-G for End-to-End Drug Development Consulting
